Merck To Stop Producing Dyslipidemia Drug Tredaptive

Merck has just announced plans to stop producing the extended-release niacin/laropiprant drug TREDAPTIVE. The drug, used to manage dyslipidemia, is not approved in the U.S. and the company is about to suspend the worldwide availability of it completely. These measures come following the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study, the results of which indicate that the drug is not nearly as effective as previously thought. The drug was found to be associated with a number of serious adverse events...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Cholesterol Source Type: news